Publications & Presentations That Leverage Our Technology

January 2021
Volume 20, 100111

Immunopeptidomics Special Issue of the journal Molecular & Cellular Proteomics

Precision Neoantigen Discovery Using Large-scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation

August 2021
Volume 27, Issue 15

Clinical Cancer Research

Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms

April 2021
J Pignon et al.

American Association for Cancer Research

Investigating the potential clinical predictive value of virus genotype, menopausal status and mutational landscape in cervical cancer tissue using a NGS based human papillomavirus (HPV) assay and whole exome sequencing (WES)

April 2021
R Pyke et al.

American Association for Cancer Research

Pan-cancer survey of HLA loss of heterozygosity using a robustly validated NGS-based machine learning algorithm

April 2021
C W Abbott et al.

American Association for Cancer Research

Longitudinal exome-scale liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy

April 2021
R Pyke et al.

American Association for Cancer Research

Accurate modeling of antigen processing and MHC peptide presentation using large-scale immunopeptidomes and a novel machine learning framework

April 2021
F C P Navarro et al.

American Association for Cancer Research

Pan-cancer shedding patterns of tumor circulating cell free DNA

April 2021
E Levy et al.

American Association for Cancer Research

Profiling tumor-infiltrating immune cells using an augmented transcriptome

March 2021
Hubert Lam et al.

Cancer Discovery

An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.

January 2021
O’Hara, Mark H et al.

The Lancet Oncology

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.

November 2020

Feng Z, Scheuenpflug J, Tan M et al.

Journal for ImmunoTherapy of Cancer 

Whole-exome sequencing based immunogenomic profiling with potential clinical applicability in circulating cell-free DNA and tissue from advanced stage colorectal cancer patients.

October 2020
Ott, Patrick A et al.

Cell

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.

September 7, 2020
Motzer, RJ, Robbins, PB, Powles, T et al.

Nature Medicine

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.

January 2020
Herrera AF, Goy A, Mehta A et al.

American Journal of Hematology

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.

September 1, 2019
Lowery, Maeve A et al.

The Lancet Gastroenterology & Hepatology

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

December 09, 2016
Dimopoulos, Meletios A et al.

The Lancet Oncology

Ibrutinib for patients with rituximab-refractory Waldenström’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

August 2016
Ashley, E

Nature Reviews Genetics

Towards precision medicine.

July 2015
Patwardhan, A, Harris, J, Leng, N et al.

Genome Medicine

Achieving high-sensitivity for clinical applications using augmented exome sequencing.